David Horn Solomon
Chief Executive Officer
More than 30 years of experience within the life sciences industry. Previously served as CEO of Silence Therapeutics, Akari Therapeutics, Bionor Parma and Zealand Pharma. Former managing partner at Sund Capital and previously headed healthcare investments at Carrot Capital Healthcare Ventures. Former Board member of TxCell (acquired by Sangamo Therapeutics), Onxeo and Promosome. Now Chairman of the Board for Advicenne Pharma and Rexgenero.
Chief Financial Officer and Chief Business Officer
More than 22 years of experience within the pharmaceutical industry, with 17 of those years in healthcare investment banking focused on M&A, financing and business development transactions for public and private life sciences companies both in the US and abroad. Previously a Partner at MTS Health Partners, and prior to MTS was a Director in the healthcare investment banking group at Bank of America. Began career at Roche as an engineer.
Chief Medical Officer
Over 30 years of experience in US and international biomedical research and clinical drug development. Previously served as Executive Vice President and Chief Medical Officer at Eagle Pharmaceuticals. Former Vice President of Clinical Research at Avanir Pharmaceuticals, Vice President of Clinical Research and Medical Affairs at BioDelivery Sciences International (BDSI), and Senior Medical Director at UCB BioSciences. Author of multiple publications and inventor of several patents. He practiced neuropsychiatry for about 17 years.
Chief Commercial Officer
Held various marketing positions in biotech and big pharma companies (GlaxoSmithKline, UCB Pharma, Alexion). Brings 18 years of experience in the commercialization of innovative drugs notably for rare diseases. Graduated from HEC Paris with a Master of Marketing and from the University Paris 7 with Masters of Science in Genetics and Immunology.
Chief Regulatory Officer
International Regulatory Affairs Strategist with 30 years’ experience in pharma and biotech industry. Previously responsible for regulatory development and product approval and maintenance in multiple therapeutic areas at Novartis, Pfizer, Amylin Pharmaceuticals, Halozyme Therapeutics and Sanofi. Experienced in the development of small molecules, biologics and gene therapy products.
Chief Quality Officer
Over 25 years in the pharmaceutical industry with dual expertise in Clinical Operations and Quality Assurance in all GxP areas at PRA, IQVIA, Pfizer and Novartis. Former Global Head of Clinical Quality Assurance, Head of GCP and PV audits for EU and Asia and EU Head of Country QA. Thorough expertise in risk-based quality management, audits and health authorities’ inspections.
Chief Preclinical Drug Development Officer
Over 25 years of experience in the management and lead of R&D projects (non-clinical / clinical / CMC) in an international hospital-university context and the pharmaceutical industry. Expertise in the development of new chemical entities in major therapeutic areas: inflammation, type 2 diabetes and oncology at Lafon, Servier and Cephalon.
Chief Pharmacology Officer
More than 15 years' experience in fundamental research and drug discovery & development in stem cells, respiratory research, cystic fibrosis, cancer and neurology in academia and industry. He was in charge of the Cancer Stem Cell project at Sanofi, then led at Servier the High Content Cellular imaging platform for different disease areas.
Co-founder, Chief Biology Officer
Specialist in experimental genetics, cell signaling and systems biology over 30 years’ in fundamental research and pharmaceutical industry. Graduated from the Moscow State University, former senior scientist and group leader at the Institute of Molecular Genetics in Moscow (Russia) and Genset (France). Former Director of the Model organisms Department at the Serono Genetics Institute. More than 50 publications and patents.
Chief Data Science Officer
Mathematician and data scientist specialized in biology with 10 year’ experience in academic, software company and biotech. PhD in computational biology expert in solving complex algorithmic problems. Previously at CNRS and CEA, leading computational genomic researches and discovery biomarker projects using statistics and machine learning. Broad knowledge of the whole omics world. Significant experience in clinical and pre-clinical biostatistics.
More than 18 years of legal affairs experience covering the full value chain within healthcare companies, listed or not. Former Head of legal affairs for a family office from inception and daily operation of a biotech group, to completion of successive fund raising. Previously operated within a pharmaceutical company for restructuring activities and divestment operations. Former legal responsible of a venture-capital firm dedicated to ICT field.